Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 8
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Sean Kelly, Md, MD | Orthopaedic Surgery | Tripler Amc, HI | $150.00 | $0 |
| Shane Morita, Md, MD | Surgery | Honolulu, HI | $150.00 | $0 |
| Dr. William Loui, M.d, M.D | Hematology & Oncology | Honolulu, HI | $150.00 | $0 |
| Alia Bana, Cns, CNS | Oncology | Santa Clara, CA | $149.71 | $0 |
| Ms. Larisa Peralta, Rn, RN | Registered Nurse | Fremont, CA | $149.71 | $0 |
| Dr. Dimple Agarwal, M.d, M.D | Internal Medicine | Palm Springs, CA | $149.46 | $0 |
| Dr. Cara Mathews, Md, MD | Gynecologic Oncology | Providence, RI | $147.11 | $0 |
| Dr. Mauricio Fernando Silva Almeida Ribeiro, Md, MD | Hematology & Oncology | Tampa, FL | $146.26 | $0 |
| Sara Mcelroy, Dnp, Aprn, Fnp-Bc, DNP, APRN, FNP-BC | Nurse Practitioner | Tampa, FL | $146.26 | $0 |
| Priscilla Merriam | Hematology & Oncology | Boston, MA | $145.94 | $0 |
| Scott Schuetze, Md, Phd, MD, PHD | Medical Oncology | Ann Arbor, MI | $142.59 | $0 |
| Dr. Felicia Williams, M.d, M.D | Surgery | Chapel Hill, NC | $139.58 | $0 |
| Dr. Shervin Oskouei, Md, MD | Orthopaedic Surgery | Atlanta, GA | $139.58 | $0 |
| Philip Wong, M.d, M.D | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $139.58 | $0 |
| Armita Bahrami, Md, MD | Clinical Pathology/Laboratory Medicine | Memphis, TN | $139.57 | $0 |
| Dr. Tarun Jain, M.d, M.D | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $139.57 | $0 |
| Shawna Watson, M.d, M.D | Orthopaedic Surgery | Sandy Springs, GA | $139.57 | $0 |
| Dr. Jatin Gandhi, Md, MD | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $139.57 | $0 |
| Susan Snouse, Pa-C, PA-C | Physician Assistant | Atlanta, GA | $139.57 | $0 |
| Dr. Jonathan Morris, M.d, M.D | Orthopaedic Surgery | Atlanta, GA | $139.57 | $0 |
| Sandra Gjorgova Gjeorgjievski, M.d, M.D | Anatomic Pathology & Clinical Pathology | Atlanta, GA | $139.57 | $0 |
| Michelle Ray, Pa-C, PA-C | Medical | Marietta, GA | $139.57 | $0 |
| Ms. Jennifer Glass, Pa-C, PA-C | Physician Assistant | Atlanta, GA | $139.57 | $0 |
| Dr. Sibo Tian, M.d, M.D | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $139.57 | $0 |
| Vaidehi Mujumdar, Md, MD | Obstetrics & Gynecology | Philadelphia, PA | $138.94 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.